Bispecific Antibodies combine two or more antigen-recognizing elements into a single construct, able to bind to two or more targets. This accounts for the fact that more than one pathway is often at the root of the disease. One approach implies engineering multiple antigen binding domains into a single molecule. At Roche, we also have designed a new format for bispecific antibodies, called CrossMAbs (where MAb stands for Monoclonal Antibody). In contrast to other technologies the CrossMAb allows production and correct chain assembly using a standard process applied for the production of therapeutic antibodies.
In December 2014, we announced the acquisition of Dutalys to strengthen our capabilities in the discovery and development of fully human, bi-specific antibodies based on their proprietary DutaMabs™ technology. The DutaMab™ technology platform further enables the development of bi-specific antibodies on a single arm of the antibody that are characterized by a high affinity and simultaneous binding against both targets, excellent stability and good manufacturing properties.